Treatment of agitation in terminally ill patients with intranasal midazolam versus subcutaneous midazolam: study protocol for a randomised controlled open-label monocentric trial (MinTU Study)

Treatment of agitation in terminally ill patients with intranasal midazolam versus subcutaneous midazolam: study protocol for a randomised controlled open-label monocentric trial (MinTU Study)

Abstract Background Intranasal (i.n.) drug application is a widely known and low-invasive route of administration that may be able to achieve rapid symptom control in terminally ill patients. According to the German S3 guideline “Palliative care for patients with incurable cancer”, benzodiazepines,...

Full description

Bibliographic Details
Main Authors: Hanna Hirschinger, Evelyn Jaeger, Stefanie Nittka, Svetlana Hetjens, Christine Lorenz, Constanze Remi, Susanne Saussele, Wolf-K. Hofmann, Deniz Gencer, Tobias Boch
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Palliative Care
Subjects:
Palliative care
Terminal agitation
Midazolam
Intranasal
Nasal spray
Online Access:https://doi.org/10.1186/s12904-023-01330-1

Internet

https://doi.org/10.1186/s12904-023-01330-1

Similar Items